Sugi Predict

Sugi Predict / Compounds / SCHEMBL1267656

SCHEMBL1267656

SCHEMBL1267656

Fc1cccc(N2CC[CH]CC2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPTF Q12830 1/20 0.49
▸ C1S P09871 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ FAAH O00519 1/20 0.44
▸ MGLL Q99685 1/20 0.44
▸ HTR1A P08908 1/20 0.44
▸ HTR7 P34969 1/20 0.44
▸ MLYCD O95822 2/20 0.43
▸ ALOX5 P09917 1/20 0.42
▸ SLC2A1 P11166 1/20 0.42
▸ SLC2A2 P11168 1/20 0.42
▸ SLC2A3 P11169 1/20 0.42
▸ POLB P06746 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SCD O00767 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072922 0.89 BPTF (0.50) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL20699709 0.87 BPTF (0.54) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL10373948 0.87 BPTF (0.54) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL30167608 0.83 ALDH1A1 (0.52) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL30407553 0.83 BPTF (0.51) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL255378 0.83 ALDH1A1 (0.52) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL3159432 0.82 SMN1; SMN2 (0.50) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL4074110 0.79 MAOB (0.40) HTTHTR1AALOX5MEN1KMT2A
SCHEMBL2300762 0.78 C1S (0.48) BPTFC1SSMN1; SMN2HTTFAAH
SCHEMBL17787657 0.78 LMNA (0.59) BPTFHTTFAAHPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1817032-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 — — EP claimed
EP-1817036-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 — — EP claimed
US-20060287303-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-12-21 — — US claimed
US-20060270653-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-11-30 — — US claimed
WO-2006058303-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 — — WO claimed
WO-2006058294-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 — — WO claimed
EP-1817036-B1 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMA (US) 2012-07-04 — — EP disclosed
US-7880007-B2 such as 1-bicyclo[2.2.1]hept-2-yl-4-(4-methoxy-2-methyl-phenyl)-piperidine, used for the treatment of chronic obstructive pulmonary disease, asthma, urinary incontinence, vision defects and Alzheimer's disease VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-01 — — US disclosed
US-7863449-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-04 — — US disclosed
EP-1415986-B1 SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS BANYU PHARMA CO LTD (JP) 2009-04-08 — — EP disclosed
EP-1817036-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 — — EP disclosed
EP-1817032-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 — — EP disclosed
US-7205417-B2 Spiro compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-04-17 — — US disclosed
US-20060287303-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-12-21 — — US disclosed
US-20060270653-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-11-30 — — US disclosed
WO-2006058294-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 — — WO disclosed
WO-2006058303-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 — — WO disclosed
US-20040259890-A1 Spiro compounds MSD K.K. (JP) 2004-12-23 — — US disclosed
CN-1538956-A Spiro compounds ������ҩ��ʽ���� 2004-10-20 — — CN disclosed
EP-1415986-A1 SPIRO COMPOUNDS BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270653-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 BPTF 2775/4885C1S 4416/4885SMN1; SMN2 3349/4885
US-20040259890-A1 Spiro compounds OPRD1, PER2, OPRK1 BPTF 3455/4885C1S 3866/4885SMN1; SMN2 350/4885
US-20060287303-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 BPTF 2775/4885C1S 4416/4885SMN1; SMN2 3349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.